- Home
- BLZE vs YMAB Comparison
BLZE vs YMAB Comparison
Compare BLZE & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLZE
- YMAB
- Stock Information
- Founded
- BLZE 2007
- YMAB 2015
- Country
- BLZE United States
- YMAB United States
- Employees
- BLZE N/A
- YMAB N/A
- Industry
- BLZE Computer Software: Prepackaged Software
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BLZE Technology
- YMAB Health Care
- Exchange
- BLZE Nasdaq
- YMAB Nasdaq
- Market Cap
- BLZE 248.6M
- YMAB 218.4M
- IPO Year
- BLZE 2021
- YMAB 2018
- Fundamental
- Price
- BLZE $4.69
- YMAB $4.69
- Analyst Decision
- BLZE Strong Buy
- YMAB Buy
- Analyst Count
- BLZE 6
- YMAB 11
- Target Price
- BLZE $10.83
- YMAB $18.73
- AVG Volume (30 Days)
- BLZE 459.6K
- YMAB 318.1K
- Earning Date
- BLZE 05-07-2025
- YMAB 05-06-2025
- Dividend Yield
- BLZE N/A
- YMAB N/A
- EPS Growth
- BLZE N/A
- YMAB N/A
- EPS
- BLZE N/A
- YMAB N/A
- Revenue
- BLZE $127,628,000.00
- YMAB $87,685,000.00
- Revenue This Year
- BLZE $15.91
- YMAB N/A
- Revenue Next Year
- BLZE $14.37
- YMAB $21.10
- P/E Ratio
- BLZE N/A
- YMAB N/A
- Revenue Growth
- BLZE 25.10
- YMAB 3.38
- 52 Week Low
- BLZE $4.07
- YMAB $3.86
- 52 Week High
- BLZE $10.00
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- BLZE 41.98
- YMAB 47.75
- Support Level
- BLZE $4.07
- YMAB $4.46
- Resistance Level
- BLZE $4.78
- YMAB $5.44
- Average True Range (ATR)
- BLZE 0.34
- YMAB 0.45
- MACD
- BLZE 0.05
- YMAB 0.07
- Stochastic Oscillator
- BLZE 63.27
- YMAB 52.53
About BLZE Backblaze Inc.
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.